Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Asian Cardiovasc Thorac Ann ; 29(9): 946-949, 2021 Nov.
Article in English | MEDLINE | ID: mdl-33334129

ABSTRACT

Ticagrelor is a potent reversible P2Y12 inhibitor with proven superiority over clopidogrel. Ticagrelor increases the tissue concentration of adenosine, thereby leading to bradyarrhythmia. This complication is reported to occur very early after initiating the drug. A randomized controlled trial reported that ticagrelor-induced pauses have an early onset without much clinical impact. However, our patient developed ticagrelor-induced hemodynamically significant sinus arrest 10 months after coronary artery stenting, which improved after stopping the drug. Ticagrelor should be considered as one of the uncommon reasons for late-onset sinus pause or bradyarrhythmia.


Subject(s)
Platelet Aggregation Inhibitors , Purinergic P2Y Receptor Antagonists , Sinus Arrest, Cardiac , Ticagrelor , Adenosine , Clopidogrel , Humans , Platelet Aggregation Inhibitors/adverse effects , Purinergic P2Y Receptor Antagonists/adverse effects , Randomized Controlled Trials as Topic , Sinus Arrest, Cardiac/chemically induced , Ticagrelor/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...